Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency

8 Oct 2024

Abstract excerpt

BACKGROUND: The epigenetic factors KAT6A (MOZ/MYST3) and KMT2A (MLL/MLL1) interact in normal hematopoiesis to regulate progenitors' self-renewal. Both proteins are recurrently translocated in AML, leading to impairment of critical differentiation pathways in these malignant cells. We evaluated the potential of different KAT6A therapeutic targeting strategies to alter the growth of KAT6A and KMT2A rearranged AMLs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Protein Degradation and Inhibitors
Share to Zebrafish Biomedical Research Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39380002
DOI: 10.1186/s13045-024-01610-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependencyPMID 39380002Read ↗

Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL LeukemiaSemantic proximity Read ↗

Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapiesSemantic proximity Read ↗

RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activationSemantic proximity Read ↗

Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.Semantic proximity Read ↗

KAT7 is a therapeutic vulnerability of <i>MLL</i> -rearranged acute myeloid leukemiaSemantic proximity Read ↗

Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemiaSemantic proximity Read ↗

Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic DevelopmentsSemantic proximity Read ↗

Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AMLSemantic proximity Read ↗

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaSemantic proximity Read ↗

The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.Semantic proximity Read ↗

The histone acetyltransferase KAT6B is required for hematopoietic stem cell development and functionSemantic proximity Read ↗

KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.